Implementation of Continuous Glucose Monitoring in the Hospital : Emergent Considerations for Remote Glucose Monitoring During the COVID-19 Pandemic
Continuous glucose monitoring (CGM) has become a widely used tool in the ambulatory setting for monitoring glucose levels, as well as detecting uncontrolled hyperglycemia, hypoglycemia, and glycemic variability. The accuracy of some CGM systems has recently improved to the point of manufacture with factory calibration and Food and Drug Administration clearance for nonadjunctive use to dose insulin. In this commentary, we analyze the answers to six questions about what is needed to bring CGM into the hospital as a reliable, safe, and effective tool. The evidence to date indicates that CGM offers promise as an effective tool for monitoring hospitalized patients. During the current coronavirus disease 2019 crisis, we hope to provide guidance to healthcare professionals, who are seeking to reduce exposure to SARS-Cov-2, as well as preserve invaluable personal protective equipment. In this commentary, we address who, what, where, when, why, and how CGM can be adopted for inpatient use.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Journal of diabetes science and technology - 14(2020), 4 vom: 01. Juli, Seite 822-832 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Galindo, Rodolfo J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood Glucose |
|---|
| Anmerkungen: |
Date Completed 20.07.2020 Date Revised 16.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/1932296820932903 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311153291 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311153291 | ||
| 003 | DE-627 | ||
| 005 | 20240216232047.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1932296820932903 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1295.xml |
| 035 | |a (DE-627)NLM311153291 | ||
| 035 | |a (NLM)32536205 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Galindo, Rodolfo J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Implementation of Continuous Glucose Monitoring in the Hospital |b Emergent Considerations for Remote Glucose Monitoring During the COVID-19 Pandemic |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.07.2020 | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Continuous glucose monitoring (CGM) has become a widely used tool in the ambulatory setting for monitoring glucose levels, as well as detecting uncontrolled hyperglycemia, hypoglycemia, and glycemic variability. The accuracy of some CGM systems has recently improved to the point of manufacture with factory calibration and Food and Drug Administration clearance for nonadjunctive use to dose insulin. In this commentary, we analyze the answers to six questions about what is needed to bring CGM into the hospital as a reliable, safe, and effective tool. The evidence to date indicates that CGM offers promise as an effective tool for monitoring hospitalized patients. During the current coronavirus disease 2019 crisis, we hope to provide guidance to healthcare professionals, who are seeking to reduce exposure to SARS-Cov-2, as well as preserve invaluable personal protective equipment. In this commentary, we address who, what, where, when, why, and how CGM can be adopted for inpatient use | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CGM | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a continuous glucose monitoring | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a hospitalized | |
| 650 | 4 | |a inpatient | |
| 650 | 4 | |a type 2 | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 700 | 1 | |a Aleppo, Grazia |e verfasserin |4 aut | |
| 700 | 1 | |a Klonoff, David C |e verfasserin |4 aut | |
| 700 | 1 | |a Spanakis, Elias K |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Shivani |e verfasserin |4 aut | |
| 700 | 1 | |a Vellanki, Priya |e verfasserin |4 aut | |
| 700 | 1 | |a Olson, Darin E |e verfasserin |4 aut | |
| 700 | 1 | |a Umpierrez, Guillermo E |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Georgia M |e verfasserin |4 aut | |
| 700 | 1 | |a Pasquel, Francisco J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of diabetes science and technology |d 2007 |g 14(2020), 4 vom: 01. Juli, Seite 822-832 |w (DE-627)NLM179163914 |x 1932-2968 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2020 |g number:4 |g day:01 |g month:07 |g pages:822-832 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1932296820932903 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2020 |e 4 |b 01 |c 07 |h 822-832 | ||